OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema

July 20th 2024

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma

July 20th 2024

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

July 20th 2024

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

July 19th 2024

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Dr Franses on Considerations for Second-Line Treatment of HCC

July 19th 2024

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Dr Machaalani on Overcoming Acquired Resistance Through AXL and c-Met Inhibition in RCC

July 19th 2024

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Dr Eckfeldt on the Implications of Improved MRD Testing in AML

July 19th 2024

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19th 2024

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

July 18th 2024

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Dr Hajj Chehade on Potential Risk Factors for irAE Development in mRCC

July 18th 2024

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML

July 18th 2024

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Dr Olazagasti on Disparities in Lung Cancer Screening Rates for Hispanic Head and Neck Cancer Survivors

July 18th 2024

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain Metastases

July 18th 2024

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.

Dr Phillips on the Evolution of MDS Treatment

July 18th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

Dr Curigliano on the Implications of T-DXd in HR+, HER2-Low and -Ultralow Breast Cancer

July 18th 2024

Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.

Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

July 18th 2024

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Dr Davis on the Utility of ADCs in Breast Cancer

July 18th 2024

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Dr Biran on the IMROZ Trial in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 17th 2024

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Dr Jhaveri on the Evolution of Treatment With ADCs in HER2-Expressing Breast Cancer

July 17th 2024

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Dr Cigliola on the Background of the SURE-01 Study in MIBC

July 17th 2024

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.